Text Size

Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Rudolf Foundation Clinic.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Rudolf Foundation Clinic
ClinicalTrials.gov Identifier:
NCT01174407
First received: November 19, 2008
Last updated: August 2, 2010
Last verified: August 2010
History of Changes
  Purpose

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.


Condition Intervention
Age-Related Macular Degeneration
 Other: cd 35, cd21, cd55

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Rudolf Foundation Clinic:

Primary Outcome Measures:
  • determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • expression rates of on AMD-patients and a healthy control group [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: September 2008
Estimated Study Completion Date: August 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
cd35 Other: cd 35, cd21, cd55
Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients with exudative age-related macular degeneration, over 55

Criteria

Inclusion Criteria:

  • Man and women over 18 years old
  • Filled out informed consent
  • Diagnosis of non-exudative/ exudative age related macular degeneneration

Exclusion Criteria:

  • Inherited retinal diseases
  • Other acquired retinal/ macular
  • Missing informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01174407

Locations
Austria
Rudolf Foundation Clinic
Vienna, Austria, 1030
Sponsors and Collaborators
Rudolf Foundation Clinic
  More Information

No publications provided by Rudolf Foundation Clinic

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Prof. Dr. Susanne Binder, Rudolf Foundation Clinic
ClinicalTrials.gov Identifier: NCT01174407     History of Changes
Other Study ID Numbers: EK08010-VK
Study First Received: November 19, 2008
Last Updated: August 2, 2010
Health Authority: Austria: Ethikkommission

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on May 19, 2013